ID   PMGT1_HUMAN             Reviewed;         660 AA.
AC   Q8WZA1; D3DQ16; Q5VST2; Q5VST3; Q9BV55; Q9H9L8; Q9NXF9; Q9NYF7;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   10-MAY-2017, entry version 138.
DE   RecName: Full=Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1;
DE            Short=POMGnT1;
DE            EC=2.4.1.- {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:11742540, ECO:0000269|PubMed:26908613, ECO:0000269|PubMed:27391550};
DE   AltName: Full=UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2;
DE            Short=GnT I.2;
GN   Name=POMGNT1; Synonyms=MGAT1.2; ORFNames=UNQ746/PRO1475;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   PATHWAY, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, VARIANTS
RP   MDDGA3 ARG-493 AND ASN-550, AND VARIANT VAL-623.
RC   TISSUE=Brain;
RX   PubMed=11709191; DOI=10.1016/S1534-5807(01)00070-3;
RA   Yoshida A., Kobayashi K., Manya H., Taniguchi K., Kano H., Mizuno M.,
RA   Inazu T., Mitsuhashi H., Takahashi S., Takeuchi M., Herrmann R.,
RA   Straub V., Talim B., Voit T., Topaloglu H., Toda T., Endo T.;
RT   "Muscular dystrophy and neuronal migration disorder caused by
RT   mutations in a glycosyltransferase, POMGnT1.";
RL   Dev. Cell 1:717-724(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS MDDGA3 LYS-223 AND
RP   TYR-269, AND VARIANT VAL-623.
RC   TISSUE=Brain;
RX   PubMed=12588800; DOI=10.1093/hmg/ddg043;
RA   Taniguchi K., Kobayashi K., Saito K., Yamanouchi H., Ohnuma A.,
RA   Hayashi Y.K., Manya H., Jin D.K., Lee M., Parano E., Falsaperla R.,
RA   Pavone P., Coster R.V., Talim B., Steinbrecher A., Straub V.,
RA   Nishino I., Topaloglu H., Voit T., Endo T., Toda T.;
RT   "Worldwide distribution and broader clinical spectrum of muscle-eye-
RT   brain disease.";
RL   Hum. Mol. Genet. 12:527-534(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-623.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   VAL-623.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-623.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   VAL-250 AND VAL-623.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 84-660 (ISOFORM 1), FUNCTION, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, PATHWAY, TISSUE SPECIFICITY,
RP   AND VARIANT VAL-623.
RC   TISSUE=Brain;
RX   PubMed=11742540; DOI=10.1042/0264-6021:3610153;
RA   Zhang W., Betel D., Schachter H.;
RT   "Cloning and expression of a novel UDP-GlcNAc:alpha-D-mannoside beta-
RT   1,2-N-acetylglucosaminyltransferase homologous to UDP-GlcNAc:alpha-3-
RT   D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.";
RL   Biochem. J. 361:153-162(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   CHARACTERIZATION OF VARIANTS MDDGA3 LYS-223; TYR-269 AND ARG-493.
RX   PubMed=12788071; DOI=10.1016/S0006-291X(03)00924-0;
RA   Manya H., Sakai K., Kobayashi K., Taniguchi K., Kawakita M., Toda T.,
RA   Endo T.;
RT   "Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in
RT   muscle-eye-brain disease.";
RL   Biochem. Biophys. Res. Commun. 306:93-97(2003).
RN   [12]
RP   IDENTIFICATION OF CATALYTIC DOMAIN, AND CHARACTERIZATION OF VARIANTS
RP   MDDGA3 LYS-223 AND TYR-269.
RX   PubMed=15207699; DOI=10.1016/j.bbrc.2004.05.129;
RA   Akasaka-Manya K., Manya H., Kobayashi K., Toda T., Endo T.;
RT   "Structure-function analysis of human protein O-linked mannose
RT   beta1,2-N-acetylglucosaminyltransferase 1, POMGnT1.";
RL   Biochem. Biophys. Res. Commun. 320:39-44(2004).
RN   [13]
RP   VARIANTS MDDGA3 HIS-265; GLN-311 AND CYS-442.
RX   PubMed=15236414; DOI=10.1002/ana.20172;
RA   Vervoort V.S., Holden K.R., Ukadike K.C., Collins J.S., Saul R.A.,
RA   Srivastava A.K.;
RT   "POMGnT1 gene alterations in a family with neurological
RT   abnormalities.";
RL   Ann. Neurol. 56:143-148(2004).
RN   [14]
RP   VARIANTS MDDGA3 SER-425 AND TYR-490.
RX   PubMed=15466003; DOI=10.1136/jmg.2004.020701;
RA   Diesen C., Saarinen A., Pihko H., Rosenlew C., Cormand B.,
RA   Dobyns W.B., Dieguez J., Valanne L., Joensuu T., Lehesjoki A.-E.;
RT   "POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain
RT   disease.";
RL   J. Med. Genet. 41:E115-E115(2004).
RN   [15]
RP   VARIANTS MDDGA3 ARG-198 AND TYR-490, AND VARIANT MDDGB3 GLN-311.
RX   PubMed=17030669; DOI=10.1001/archneur.63.10.1491;
RA   Biancheri R., Bertini E., Falace A., Pedemonte M., Rossi A.,
RA   D'Amico A., Scapolan S., Bergamino L., Petrini S., Cassandrini D.,
RA   Broda P., Manfredi M., Zara F., Santorelli F.M., Minetti C., Bruno C.;
RT   "POMGnT1 mutations in congenital muscular dystrophy: genotype-
RT   phenotype correlation and expanded clinical spectrum.";
RL   Arch. Neurol. 63:1491-1495(2006).
RN   [16]
RP   VARIANTS MDDGA3 PRO-176; HIS-367 AND HIS-427, AND VARIANT MDDGB3
RP   TYR-490.
RX   PubMed=19067344; DOI=10.1002/ana.21482;
RA   Clement E., Mercuri E., Godfrey C., Smith J., Robb S., Kinali M.,
RA   Straub V., Bushby K., Manzur A., Talim B., Cowan F., Quinlivan R.,
RA   Klein A., Longman C., McWilliam R., Topaloglu H., Mein R., Abbs S.,
RA   North K., Barkovich A.J., Rutherford M., Muntoni F.;
RT   "Brain involvement in muscular dystrophies with defective dystroglycan
RT   glycosylation.";
RL   Ann. Neurol. 64:573-582(2008).
RN   [17]
RP   VARIANT MDDGC3 ASN-556, AND CHARACTERIZATION OF VARIANT MDDGC3
RP   ASN-556.
RX   PubMed=18195152; DOI=10.1001/archneurol.2007.2;
RA   Clement E.M., Godfrey C., Tan J., Brockington M., Torelli S., Feng L.,
RA   Brown S.C., Jimenez-Mallebrera C., Sewry C.A., Longman C., Mein R.,
RA   Abbs S., Vajsar J., Schachter H., Muntoni F.;
RT   "Mild POMGnT1 mutations underlie a novel limb-girdle muscular
RT   dystrophy variant.";
RL   Arch. Neurol. 65:137-141(2008).
RN   [18]
RP   VARIANT MDDGB3 PRO-605.
RX   PubMed=19299310; DOI=10.1212/01.wnl.0000346518.68110.60;
RA   Mercuri E., Messina S., Bruno C., Mora M., Pegoraro E., Comi G.P.,
RA   D'Amico A., Aiello C., Biancheri R., Berardinelli A., Boffi P.,
RA   Cassandrini D., Laverda A., Moggio M., Morandi L., Moroni I., Pane M.,
RA   Pezzani R., Pichiecchio A., Pini A., Minetti C., Mongini T.,
RA   Mottarelli E., Ricci E., Ruggieri A., Saredi S., Scuderi C., Tessa A.,
RA   Toscano A., Tortorella G., Trevisan C.P., Uggetti C., Vasco G.,
RA   Santorelli F.M., Bertini E.;
RT   "Congenital muscular dystrophies with defective glycosylation of
RT   dystroglycan: a population study.";
RL   Neurology 72:1802-1809(2009).
RN   [19]
RP   INVOLVEMENT IN RP76, VARIANTS RP76 LYS-156; SER-287 AND ALA-502,
RP   CHARACTERIZATION OF VARIANTS RP76 LYS-156 AND SER-287, FUNCTION,
RP   CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=26908613; DOI=10.1093/hmg/ddw022;
RA   Xu M., Yamada T., Sun Z., Eblimit A., Lopez I., Wang F., Manya H.,
RA   Xu S., Zhao L., Li Y., Kimchi A., Sharon D., Sui R., Endo T.,
RA   Koenekoop R.K., Chen R.;
RT   "Mutations in POMGNT1 cause non-syndromic retinitis pigmentosa.";
RL   Hum. Mol. Genet. 25:1479-1488(2016).
RN   [20]
RP   INVOLVEMENT IN RP76, VARIANT RP76 ARG-120, CHARACTERIZATION OF VARIANT
RP   RP76 ARG-120, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=27391550; DOI=10.1167/iovs.16-19463;
RA   Wang N.H., Chen S.J., Yang C.F., Chen H.W., Chuang H.P., Lu Y.H.,
RA   Chen C.H., Wu J.Y., Niu D.M., Chen Y.T.;
RT   "Homozygosity Mapping and Whole-Genome Sequencing Links a Missense
RT   Mutation in POMGNT1 to Autosomal Recessive Retinitis Pigmentosa.";
RL   Invest. Ophthalmol. Vis. Sci. 57:3601-3609(2016).
CC   -!- FUNCTION: Participates in O-mannosyl glycosylation. May be
CC       responsible for the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-
CC       Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated
CC       proteins. Is specific for alpha linked terminal mannose and does
CC       not have MGAT3, MGAT4, MGAT5, MGAT7 or MGAT8 activity.
CC       {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:11742540,
CC       ECO:0000269|PubMed:26908613, ECO:0000269|PubMed:27391550}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-glucosamine + O-alpha-D-
CC       mannosylprotein = UDP + N-acetyl-beta-D-glucosaminyl-(1->2)-O-
CC       alpha-D-mannosylprotein. {ECO:0000269|PubMed:11709191,
CC       ECO:0000269|PubMed:11742540, ECO:0000269|PubMed:26908613,
CC       ECO:0000269|PubMed:27391550}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.85 mM for mannosylpeptide {ECO:0000269|PubMed:11709191,
CC         ECO:0000269|PubMed:11742540};
CC         KM=0.73 mM for UDP-GlcNAc {ECO:0000269|PubMed:11709191,
CC         ECO:0000269|PubMed:11742540};
CC         KM=30 mM for Man(alpha1-)O-benzyl {ECO:0000269|PubMed:11709191,
CC         ECO:0000269|PubMed:11742540};
CC         KM=12 mM for CYA[Man(alpha1-)O-T]AV
CC         {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:11742540};
CC       pH dependence:
CC         Optimum pH is 6.0. {ECO:0000269|PubMed:11709191,
CC         ECO:0000269|PubMed:11742540};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:11742540,
CC       ECO:0000269|PubMed:26908613, ECO:0000269|PubMed:27391550}.
CC   -!- INTERACTION:
CC       Q8TBB1:LNX1; NbExp=3; IntAct=EBI-3912424, EBI-739832;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305};
CC       Single-pass type II membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8WZA1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WZA1-2; Sequence=VSP_054029;
CC         Note=Ref.4 (AK056186) sequence is in conflict in position:
CC         636:G->K. No experimental confirmation available. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Constitutively expressed. An additional weaker
CC       band is also detected in spinal cord, lymph node, and trachea.
CC       Expressed especially in astrocytes. Also expressed in immature and
CC       mature neurons. {ECO:0000269|PubMed:11709191,
CC       ECO:0000269|PubMed:11742540}.
CC   -!- DOMAIN: Amino acid residues between 299-311 are important for both
CC       protein expression and enzymatic activity. The minimal catalytic
CC       domain is located between positions 299-651. Single amino acid
CC       substitutions in the stem domain from MEB patients abolished the
CC       activity of the membrane-bound form but not the soluble form. This
CC       suggests that the stem domain of the soluble form is unnecessary
CC       for activity, but that some amino acids play a crucial role in the
CC       membrane-bound form.
CC   -!- DISEASE: Muscular dystrophy-dystroglycanopathy congenital with
CC       brain and eye anomalies A3 (MDDGA3) [MIM:253280]: An autosomal
CC       recessive disorder characterized by congenital muscular dystrophy,
CC       ocular abnormalities, cobblestone lissencephaly, and cerebellar
CC       and pontine hypoplasia. Patients present severe congenital myopia,
CC       congenital glaucoma, pallor of the optic disks, retinal
CC       hypoplasia, mental retardation, hydrocephalus, abnormal
CC       electroencephalograms, generalized muscle weakness and myoclonic
CC       jerks. Included diseases are the more severe Walker-Warburg
CC       syndrome and the slightly less severe muscle-eye-brain disease.
CC       {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:12588800,
CC       ECO:0000269|PubMed:12788071, ECO:0000269|PubMed:15207699,
CC       ECO:0000269|PubMed:15236414, ECO:0000269|PubMed:15466003,
CC       ECO:0000269|PubMed:17030669, ECO:0000269|PubMed:19067344}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Muscular dystrophy-dystroglycanopathy congenital with
CC       mental retardation B3 (MDDGB3) [MIM:613151]: An autosomal
CC       recessive disorder characterized by congenital muscular dystrophy
CC       associated with mental retardation and mild structural brain
CC       abnormalities. Clinical features include mental retardation, white
CC       matter changes, cerebellar cysts, pontine hypoplasia, myopia,
CC       optic atrophy, decreased alpha-dystroglycan on muscle biopsy and
CC       increased serum creatine kinase. {ECO:0000269|PubMed:17030669,
CC       ECO:0000269|PubMed:19067344, ECO:0000269|PubMed:19299310}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Muscular dystrophy-dystroglycanopathy limb-girdle C3
CC       (MDDGC3) [MIM:613157]: A rare form of limb-girdle muscular
CC       dystrophy with normal cognition. Muscle biopsy shows dystrophic
CC       changes with variable staining for glycosylated alpha-
CC       dystroglycan. {ECO:0000269|PubMed:18195152}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Retinitis pigmentosa 76 (RP76) [MIM:617123]: A form of
CC       retinitis pigmentosa, a retinal dystrophy belonging to the group
CC       of pigmentary retinopathies. Retinitis pigmentosa is characterized
CC       by retinal pigment deposits visible on fundus examination and
CC       primary loss of rod photoreceptor cells followed by secondary loss
CC       of cone photoreceptors. Patients typically have night vision
CC       blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field
CC       and eventually central vision as well. RP76 inheritance is
CC       autosomal recessive. {ECO:0000269|PubMed:26908613,
CC       ECO:0000269|PubMed:27391550}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 13 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14207.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Protein O-linked-mannose beta-1,2-N-
CC       acetylglucosaminyltransferase 1;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_559";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB057356; BAB71960.1; -; mRNA.
DR   EMBL; AY358592; AAQ88955.1; -; mRNA.
DR   EMBL; AK000284; BAA91053.1; -; mRNA.
DR   EMBL; AK022727; BAB14207.1; ALT_INIT; mRNA.
DR   EMBL; AK056186; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL672043; CAH72470.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06932.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06933.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06935.1; -; Genomic_DNA.
DR   EMBL; BC001471; AAH01471.1; -; mRNA.
DR   EMBL; AF250859; AAF71270.2; -; mRNA.
DR   CCDS; CCDS531.1; -. [Q8WZA1-1]
DR   CCDS; CCDS57995.1; -. [Q8WZA1-2]
DR   RefSeq; NP_060209.3; NM_017739.3.
DR   RefSeq; XP_006710819.1; XM_006710756.1. [Q8WZA1-2]
DR   RefSeq; XP_016857179.1; XM_017001690.1. [Q8WZA1-1]
DR   UniGene; Hs.525134; -.
DR   PDB; 5GGF; X-ray; 2.49 A; A/B/C=92-660.
DR   PDB; 5GGG; X-ray; 3.00 A; A=92-660.
DR   PDB; 5GGI; X-ray; 2.60 A; A/B=92-660.
DR   PDB; 5GGJ; X-ray; 1.42 A; A/B=92-250.
DR   PDB; 5GGK; X-ray; 1.30 A; A/B=92-250.
DR   PDB; 5GGL; X-ray; 1.27 A; A/B=92-250.
DR   PDB; 5GGN; X-ray; 1.21 A; A/B=92-250.
DR   PDB; 5GGO; X-ray; 1.50 A; A/B=92-250.
DR   PDB; 5GGP; X-ray; 1.60 A; A/B=92-250.
DR   PDBsum; 5GGF; -.
DR   PDBsum; 5GGG; -.
DR   PDBsum; 5GGI; -.
DR   PDBsum; 5GGJ; -.
DR   PDBsum; 5GGK; -.
DR   PDBsum; 5GGL; -.
DR   PDBsum; 5GGN; -.
DR   PDBsum; 5GGO; -.
DR   PDBsum; 5GGP; -.
DR   ProteinModelPortal; Q8WZA1; -.
DR   SMR; Q8WZA1; -.
DR   BioGrid; 120763; 23.
DR   IntAct; Q8WZA1; 8.
DR   STRING; 9606.ENSP00000361052; -.
DR   ChEMBL; CHEMBL2321629; -.
DR   CAZy; GT13; Glycosyltransferase Family 13.
DR   iPTMnet; Q8WZA1; -.
DR   PhosphoSitePlus; Q8WZA1; -.
DR   SwissPalm; Q8WZA1; -.
DR   BioMuta; POMGNT1; -.
DR   DMDM; 311033411; -.
DR   EPD; Q8WZA1; -.
DR   MaxQB; Q8WZA1; -.
DR   PaxDb; Q8WZA1; -.
DR   PeptideAtlas; Q8WZA1; -.
DR   PRIDE; Q8WZA1; -.
DR   DNASU; 55624; -.
DR   Ensembl; ENST00000371984; ENSP00000361052; ENSG00000085998. [Q8WZA1-1]
DR   Ensembl; ENST00000371992; ENSP00000361060; ENSG00000085998. [Q8WZA1-2]
DR   GeneID; 55624; -.
DR   KEGG; hsa:55624; -.
DR   UCSC; uc001cpe.4; human. [Q8WZA1-1]
DR   CTD; 55624; -.
DR   DisGeNET; 55624; -.
DR   GeneCards; POMGNT1; -.
DR   GeneReviews; POMGNT1; -.
DR   HGNC; HGNC:19139; POMGNT1.
DR   HPA; HPA044518; -.
DR   MalaCards; POMGNT1; -.
DR   MIM; 253280; phenotype.
DR   MIM; 606822; gene.
DR   MIM; 613151; phenotype.
DR   MIM; 613157; phenotype.
DR   MIM; 617123; phenotype.
DR   neXtProt; NX_Q8WZA1; -.
DR   OpenTargets; ENSG00000085998; -.
DR   Orphanet; 206564; Autosomal recessive limb-girdle muscular dystrophy type 2O.
DR   Orphanet; 370959; Congenital muscular dystrophy with cerebellar involvement.
DR   Orphanet; 588; Muscle-eye-brain disease.
DR   Orphanet; 899; Walker-Warburg syndrome.
DR   PharmGKB; PA142671161; -.
DR   eggNOG; ENOG410IFXX; Eukaryota.
DR   eggNOG; ENOG410YMAS; LUCA.
DR   GeneTree; ENSGT00530000063632; -.
DR   HOGENOM; HOG000231121; -.
DR   HOVERGEN; HBG055279; -.
DR   InParanoid; Q8WZA1; -.
DR   KO; K09666; -.
DR   OMA; PYSVKKP; -.
DR   OrthoDB; EOG091G00JT; -.
DR   PhylomeDB; Q8WZA1; -.
DR   TreeFam; TF320555; -.
DR   Reactome; R-HSA-5173105; O-linked glycosylation.
DR   UniPathway; UPA00378; -.
DR   ChiTaRS; POMGNT1; human.
DR   GeneWiki; POMGNT1; -.
DR   GenomeRNAi; 55624; -.
DR   PRO; PR:Q8WZA1; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000085998; -.
DR   CleanEx; HS_POMGNT1; -.
DR   ExpressionAtlas; Q8WZA1; baseline and differential.
DR   Genevisible; Q8WZA1; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0047223; F:beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity; IDA:MGI.
DR   GO; GO:0006493; P:protein O-linked glycosylation; IDA:MGI.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR004139; Glyco_trans_13.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR10468; PTHR10468; 1.
DR   Pfam; PF03071; GNT-I; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Congenital muscular dystrophy; Disease mutation; Dystroglycanopathy;
KW   Glycosyltransferase; Golgi apparatus; Limb-girdle muscular dystrophy;
KW   Lissencephaly; Manganese; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Retinitis pigmentosa; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    660       Protein O-linked-mannose beta-1,2-N-
FT                                acetylglucosaminyltransferase 1.
FT                                /FTId=PRO_0000191390.
FT   TOPO_DOM      1     37       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     38     58       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     59    660       Lumenal. {ECO:0000255}.
FT   COMPBIAS    263    267       Poly-Arg.
FT   MOD_RES       7      7       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     624    660       VGVPASPYSVKKPPSVTPIFLEPPPKEEGAPGAPEQT ->
FT                                SEEATLSHPNFPGATPKGGGSPRSPRTDMRPPPGPCGAGPG
FT                                SESNLFIDCPEGLENRPNLEGLDFFLGWNAALRVGLALTQE
FT                                TAVPNPWTGPAGAHMLTQTHSETLRHWTRPPLSLLFVQISK
FT                                AG (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054029.
FT   VARIANT     120    120       L -> R (in RP76; no effect on protein
FT                                abundance; reduced
FT                                acetylglucosaminyltransferase activity).
FT                                {ECO:0000269|PubMed:27391550}.
FT                                /FTId=VAR_077054.
FT   VARIANT     156    156       E -> K (in RP76; reduced
FT                                acetylglucosaminyltransferase activity).
FT                                {ECO:0000269|PubMed:26908613}.
FT                                /FTId=VAR_076524.
FT   VARIANT     176    176       T -> P (in MDDGA3; dbSNP:rs386834030).
FT                                {ECO:0000269|PubMed:19067344}.
FT                                /FTId=VAR_065021.
FT   VARIANT     198    198       S -> R (in MDDGA3; dbSNP:rs386834032).
FT                                {ECO:0000269|PubMed:17030669}.
FT                                /FTId=VAR_065022.
FT   VARIANT     223    223       E -> K (in MDDGA3; specific activity
FT                                abolished in the membrane bound form but
FT                                not the soluble form; dbSNP:rs386834036).
FT                                {ECO:0000269|PubMed:12588800,
FT                                ECO:0000269|PubMed:12788071,
FT                                ECO:0000269|PubMed:15207699}.
FT                                /FTId=VAR_023101.
FT   VARIANT     250    250       E -> V (in dbSNP:rs17855359).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030645.
FT   VARIANT     265    265       R -> H (in MDDGA3; found on the same
FT                                allele as Q-311; unknown pathological
FT                                significance; dbSNP:rs386834010).
FT                                {ECO:0000269|PubMed:15236414}.
FT                                /FTId=VAR_023102.
FT   VARIANT     269    269       C -> Y (in MDDGA3; specific activity
FT                                abolished of the membrane bound form but
FT                                not the soluble form; dbSNP:rs386834037).
FT                                {ECO:0000269|PubMed:12588800,
FT                                ECO:0000269|PubMed:12788071,
FT                                ECO:0000269|PubMed:15207699}.
FT                                /FTId=VAR_023103.
FT   VARIANT     287    287       I -> S (in RP76; reduced
FT                                acetylglucosaminyltransferase activity;
FT                                dbSNP:rs200863680).
FT                                {ECO:0000269|PubMed:26908613}.
FT                                /FTId=VAR_076525.
FT   VARIANT     311    311       R -> Q (in MDDGA3 and MDDGB3;
FT                                dbSNP:rs193919336).
FT                                {ECO:0000269|PubMed:15236414,
FT                                ECO:0000269|PubMed:17030669}.
FT                                /FTId=VAR_023104.
FT   VARIANT     367    367       R -> H (in MDDGA3; dbSNP:rs762972459).
FT                                {ECO:0000269|PubMed:19067344}.
FT                                /FTId=VAR_065023.
FT   VARIANT     425    425       W -> S (in MDDGA3; dbSNP:rs386834011).
FT                                {ECO:0000269|PubMed:15466003}.
FT                                /FTId=VAR_023105.
FT   VARIANT     427    427       D -> H (in MDDGA3).
FT                                {ECO:0000269|PubMed:19067344}.
FT                                /FTId=VAR_065024.
FT   VARIANT     442    442       R -> C (in MDDGA3; dbSNP:rs28940869).
FT                                {ECO:0000269|PubMed:15236414}.
FT                                /FTId=VAR_023106.
FT   VARIANT     490    490       C -> Y (in MDDGA3 and MDDGB3;
FT                                dbSNP:rs267606960).
FT                                {ECO:0000269|PubMed:15466003,
FT                                ECO:0000269|PubMed:17030669,
FT                                ECO:0000269|PubMed:19067344}.
FT                                /FTId=VAR_023107.
FT   VARIANT     493    493       P -> R (in MDDGA3; specific activity
FT                                abolished; dbSNP:rs28942068).
FT                                {ECO:0000269|PubMed:11709191,
FT                                ECO:0000269|PubMed:12788071}.
FT                                /FTId=VAR_023108.
FT   VARIANT     502    502       G -> A (in RP76).
FT                                {ECO:0000269|PubMed:26908613}.
FT                                /FTId=VAR_076526.
FT   VARIANT     504    504       V -> I (in dbSNP:rs17102066).
FT                                /FTId=VAR_030646.
FT   VARIANT     550    550       S -> N (in MDDGA3; dbSNP:rs193919335).
FT                                {ECO:0000269|PubMed:11709191}.
FT                                /FTId=VAR_023109.
FT   VARIANT     556    556       D -> N (in MDDGC3; normal enzyme activity
FT                                but altered kinetic properties;
FT                                dbSNP:rs74374973).
FT                                {ECO:0000269|PubMed:18195152}.
FT                                /FTId=VAR_065025.
FT   VARIANT     605    605       R -> P (in MDDGB3; dbSNP:rs267606962).
FT                                {ECO:0000269|PubMed:19299310}.
FT                                /FTId=VAR_065026.
FT   VARIANT     623    623       M -> V (in dbSNP:rs6659553).
FT                                {ECO:0000269|PubMed:11709191,
FT                                ECO:0000269|PubMed:11742540,
FT                                ECO:0000269|PubMed:12588800,
FT                                ECO:0000269|PubMed:12975309,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023110.
FT   CONFLICT    636    636       P -> L (in Ref. 3; BAA91053).
FT                                {ECO:0000305}.
FT   STRAND       98    108       {ECO:0000244|PDB:5GGN}.
FT   STRAND      110    114       {ECO:0000244|PDB:5GGN}.
FT   STRAND      117    122       {ECO:0000244|PDB:5GGN}.
FT   STRAND      125    127       {ECO:0000244|PDB:5GGP}.
FT   STRAND      130    136       {ECO:0000244|PDB:5GGN}.
FT   TURN        138    140       {ECO:0000244|PDB:5GGN}.
FT   STRAND      143    149       {ECO:0000244|PDB:5GGN}.
FT   HELIX       156    166       {ECO:0000244|PDB:5GGN}.
FT   STRAND      171    179       {ECO:0000244|PDB:5GGN}.
FT   HELIX       187    195       {ECO:0000244|PDB:5GGN}.
FT   HELIX       201    203       {ECO:0000244|PDB:5GGN}.
FT   STRAND      209    215       {ECO:0000244|PDB:5GGN}.
FT   STRAND      220    226       {ECO:0000244|PDB:5GGN}.
FT   STRAND      229    233       {ECO:0000244|PDB:5GGG}.
FT   STRAND      238    245       {ECO:0000244|PDB:5GGN}.
FT   HELIX       249    252       {ECO:0000244|PDB:5GGF}.
FT   HELIX       261    269       {ECO:0000244|PDB:5GGF}.
FT   HELIX       276    279       {ECO:0000244|PDB:5GGF}.
FT   STRAND      281    283       {ECO:0000244|PDB:5GGF}.
FT   TURN        298    301       {ECO:0000244|PDB:5GGF}.
FT   STRAND      304    308       {ECO:0000244|PDB:5GGF}.
FT   HELIX       312    323       {ECO:0000244|PDB:5GGF}.
FT   HELIX       330    332       {ECO:0000244|PDB:5GGF}.
FT   STRAND      333    339       {ECO:0000244|PDB:5GGF}.
FT   HELIX       342    350       {ECO:0000244|PDB:5GGF}.
FT   STRAND      354    358       {ECO:0000244|PDB:5GGF}.
FT   HELIX       364    382       {ECO:0000244|PDB:5GGF}.
FT   STRAND      387    393       {ECO:0000244|PDB:5GGF}.
FT   STRAND      396    398       {ECO:0000244|PDB:5GGF}.
FT   HELIX       402    415       {ECO:0000244|PDB:5GGF}.
FT   STRAND      419    424       {ECO:0000244|PDB:5GGF}.
FT   TURN        431    433       {ECO:0000244|PDB:5GGF}.
FT   STRAND      440    445       {ECO:0000244|PDB:5GGF}.
FT   STRAND      449    454       {ECO:0000244|PDB:5GGF}.
FT   HELIX       455    460       {ECO:0000244|PDB:5GGF}.
FT   HELIX       463    465       {ECO:0000244|PDB:5GGF}.
FT   HELIX       475    480       {ECO:0000244|PDB:5GGF}.
FT   HELIX       482    485       {ECO:0000244|PDB:5GGF}.
FT   STRAND      489    500       {ECO:0000244|PDB:5GGF}.
FT   STRAND      504    507       {ECO:0000244|PDB:5GGI}.
FT   HELIX       510    516       {ECO:0000244|PDB:5GGI}.
FT   TURN        517    519       {ECO:0000244|PDB:5GGI}.
FT   HELIX       533    536       {ECO:0000244|PDB:5GGF}.
FT   HELIX       538    551       {ECO:0000244|PDB:5GGF}.
FT   STRAND      552    554       {ECO:0000244|PDB:5GGG}.
FT   HELIX       564    566       {ECO:0000244|PDB:5GGF}.
FT   STRAND      574    583       {ECO:0000244|PDB:5GGF}.
FT   HELIX       588    596       {ECO:0000244|PDB:5GGF}.
FT   STRAND      606    608       {ECO:0000244|PDB:5GGF}.
FT   STRAND      611    616       {ECO:0000244|PDB:5GGF}.
FT   STRAND      619    627       {ECO:0000244|PDB:5GGF}.
FT   HELIX       630    634       {ECO:0000244|PDB:5GGF}.
SQ   SEQUENCE   660 AA;  75252 MW;  C58D0E543E033F17 CRC64;
     MDDWKPSPLI KPFGARKKRS WYLTWKYKLT NQRALRRFCQ TGAVLFLLVT VIVNIKLILD
     TRRAISEANE DPEPEQDYDE ALGRLEPPRR RGSGPRRVLD VEVYSSRSKV YVAVDGTTVL
     EDEAREQGRG IHVIVLNQAT GHVMAKRVFD TYSPHEDEAM VLFLNMVAPG RVLICTVKDE
     GSFHLKDTAK ALLRSLGSQA GPALGWRDTW AFVGRKGGPV FGEKHSKSPA LSSWGDPVLL
     KTDVPLSSAE EAECHWADTE LNRRRRRFCS KVEGYGSVCS CKDPTPIEFS PDPLPDNKVL
     NVPVAVIAGN RPNYLYRMLR SLLSAQGVSP QMITVFIDGY YEEPMDVVAL FGLRGIQHTP
     ISIKNARVSQ HYKASLTATF NLFPEAKFAV VLEEDLDIAV DFFSFLSQSI HLLEEDDSLY
     CISAWNDQGY EHTAEDPALL YRVETMPGLG WVLRRSLYKE ELEPKWPTPE KLWDWDMWMR
     MPEQRRGREC IIPDVSRSYH FGIVGLNMNG YFHEAYFKKH KFNTVPGVQL RNVDSLKKEA
     YEVEVHRLLS EAEVLDHSKN PCEDSFLPDT EGHTYVAFIR MEKDDDFTTW TQLAKCLHIW
     DLDVRGNHRG LWRLFRKKNH FLMVGVPASP YSVKKPPSVT PIFLEPPPKE EGAPGAPEQT
//
